Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Narcolepsy Breakthrough | Centessa's ORX750 poised to revolutionize $2B narcolepsy treatment market with potential for superior efficacy and once-daily dosing |
Pipeline Diversity | Beyond narcolepsy, Centessa's SerpinPC shows promise in hemophilia treatment, demonstrating the company's multi-faceted approach to drug development |
Market Momentum | CNTA stock surges 108% YTD, with analysts projecting further 50-100% growth potential pending crucial clinical data expected in late 2024 |
Financial Fortitude | Solid balance sheet with more cash than debt positions Centessa for continued R&D investment, while analyst targets range from $24 to $35 |
Metrics to compare | CNTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNTAPeersSector | |
---|---|---|---|---|
P/E Ratio | −14.0x | −2.2x | −0.5x | |
PEG Ratio | −1.80 | −0.02 | 0.00 | |
Price/Book | 4.5x | 0.9x | 2.6x | |
Price / LTM Sales | 329.8x | 10.3x | 3.0x | |
Upside (Analyst Target) | 63.4% | 213.2% | 56.6% | |
Fair Value Upside | Unlock | 29.9% | 10.1% | Unlock |